JP2019504064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504064A5 JP2019504064A5 JP2018535391A JP2018535391A JP2019504064A5 JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5 JP 2018535391 A JP2018535391 A JP 2018535391A JP 2018535391 A JP2018535391 A JP 2018535391A JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 124
- 239000000203 mixture Substances 0.000 claims 65
- 239000000427 antigen Substances 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 18
- 210000003205 muscle Anatomy 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000020431 spinal cord injury Diseases 0.000 claims 11
- 102000004472 Myostatin Human genes 0.000 claims 10
- 108010056852 Myostatin Proteins 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 201000000585 muscular atrophy Diseases 0.000 claims 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 5
- 210000000577 adipose tissue Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 210000002161 motor neuron Anatomy 0.000 claims 3
- 206010002261 Androgen deficiency Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010068836 Metabolic myopathy Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000000593 adipose tissue white Anatomy 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000005228 liver tissue Anatomy 0.000 claims 2
- 230000037323 metabolic rate Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000005996 muscular dysfunction Effects 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000003486 adipose tissue brown Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000002638 denervation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 230000002806 hypometabolic effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 230000013190 lipid storage Effects 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 230000010120 metabolic dysregulation Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000007372 neural signaling Effects 0.000 claims 1
- 238000011859 neuroprotective therapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022185469A JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276698P | 2016-01-08 | 2016-01-08 | |
| US62/276,698 | 2016-01-08 | ||
| US201662328597P | 2016-04-27 | 2016-04-27 | |
| US62/328,597 | 2016-04-27 | ||
| US201662333810P | 2016-05-09 | 2016-05-09 | |
| US201662333816P | 2016-05-09 | 2016-05-09 | |
| US62/333,810 | 2016-05-09 | ||
| US62/333,816 | 2016-05-09 | ||
| USPCT/US2016/052014 | 2016-09-15 | ||
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
| US201662413278P | 2016-10-26 | 2016-10-26 | |
| US62/413,278 | 2016-10-26 | ||
| PCT/US2017/012606 WO2017120523A2 (en) | 2016-01-08 | 2017-01-06 | Anti-pro/latent myostatin antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022185469A Division JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504064A JP2019504064A (ja) | 2019-02-14 |
| JP2019504064A5 true JP2019504064A5 (enExample) | 2020-03-12 |
Family
ID=59274466
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535391A Pending JP2019504064A (ja) | 2016-01-08 | 2017-01-06 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2022185469A Active JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A Pending JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022185469A Active JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A Pending JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10287345B2 (enExample) |
| EP (1) | EP3400240A2 (enExample) |
| JP (3) | JP2019504064A (enExample) |
| KR (1) | KR20180094110A (enExample) |
| CN (2) | CN115814077A (enExample) |
| AU (2) | AU2017206069A1 (enExample) |
| MX (3) | MX2018008369A (enExample) |
| SG (1) | SG11201805709RA (enExample) |
| WO (1) | WO2017120523A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| KR102854939B1 (ko) | 2012-08-24 | 2025-09-03 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
| BR112018004981A2 (pt) | 2015-09-15 | 2018-10-09 | Scholar Rock, Inc. | anticorpos anti-pró-miostatina/miostatina latente e usos destes. |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR20230169484A (ko) | 2016-06-13 | 2023-12-15 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| AU2018205270B2 (en) | 2017-01-06 | 2022-08-11 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| JP7653257B2 (ja) * | 2018-03-23 | 2025-03-28 | サイトー | 骨格筋肥大誘発剤としてのａｌｋ５阻害剤 |
| US11578325B2 (en) | 2018-05-24 | 2023-02-14 | David Berz | Methods and formulations for the treatment of obesity and obesity-related metabolic diseases |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| US11455381B2 (en) | 2020-04-21 | 2022-09-27 | CIELO Enterprise Solutions, Inc. | Systems and methods for providing multiple functionalities associated with a QR code |
| EP4358995B1 (en) | 2021-06-23 | 2025-12-03 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| EP4426306A1 (en) * | 2021-10-06 | 2024-09-11 | F. Hoffmann-La Roche AG | Novel combined administration |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| DE69432815T2 (de) | 1993-03-19 | 2003-12-11 | The Johns Hopkins University School Of Medicine, Baltimore | Wachstumsfaktor-8 |
| US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| EP1158997A2 (en) | 1999-03-09 | 2001-12-05 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| PL357017A1 (en) | 2000-01-28 | 2004-07-12 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| ATE494304T1 (de) | 2000-06-16 | 2011-01-15 | Human Genome Sciences Inc | Immunspezifisch bindende antikörper gegen blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| DE60128914T2 (de) | 2001-10-05 | 2008-05-08 | Affimed Therapeutics Ag | Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation |
| KR20130001318A (ko) | 2002-07-19 | 2013-01-03 | 애보트 바이오테크놀로지 리미티드 | ＴＮＦα 관련 질환의 치료 |
| US7572599B2 (en) | 2002-09-16 | 2009-08-11 | The Johns Hopkins University School Of Medicine | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| RU2377253C2 (ru) | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
| RS52815B (sr) | 2002-12-20 | 2013-10-31 | Amgen Inc. | Vezivna sredstva koja inhibiraju miostatin |
| MXPA06007514A (es) | 2003-12-31 | 2006-08-31 | Schering Plough Ltd | Vacuna para mejorar el crecimiento a base de epitopes neutralizantes. |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| EP1733041B1 (en) | 2004-03-23 | 2012-05-09 | Eli Lilly & Company | Anti-myostatin antibodies |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7566772B2 (en) | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| CA2605723A1 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
| EP3327033A1 (en) * | 2005-08-19 | 2018-05-30 | Wyeth LLC | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| EP2054434B1 (en) | 2006-08-03 | 2017-03-15 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| WO2008030706A2 (en) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| CA2693178C (en) | 2006-11-29 | 2018-12-04 | Nationwide Children's Hospital, Inc. | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| CA2678493A1 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia University In The City Of New York | Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| EP2129742B1 (en) | 2007-03-30 | 2012-01-25 | Merck Patent GmbH | Birefingent layer with negative optical dispersion |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| BR112012007563A2 (pt) | 2009-10-01 | 2019-09-24 | Covita Ltd | peptídeos sintéticos antagonistas de miostatina |
| SG10201501767VA (en) | 2010-03-10 | 2015-05-28 | Genmab As | Monoclonal antibodies against c-met |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| NZ608206A (en) | 2010-08-16 | 2015-02-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| MX350355B (es) | 2011-11-14 | 2017-09-04 | Regeneron Pharma | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| KR101704893B1 (ko) * | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| MX388059B (es) | 2012-11-06 | 2025-03-19 | Scholar Rock Inc | Composiciones y metodos para modular la comunicacion celular. |
| HRP20251426T1 (hr) | 2013-05-06 | 2026-01-02 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| WO2015070158A1 (en) * | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| CA2982810A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| BR112018004981A2 (pt) | 2015-09-15 | 2018-10-09 | Scholar Rock, Inc. | anticorpos anti-pró-miostatina/miostatina latente e usos destes. |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR20230169484A (ko) | 2016-06-13 | 2023-12-15 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| AU2018205270B2 (en) | 2017-01-06 | 2022-08-11 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
-
2017
- 2017-01-06 KR KR1020187022432A patent/KR20180094110A/ko active Pending
- 2017-01-06 WO PCT/US2017/012606 patent/WO2017120523A2/en not_active Ceased
- 2017-01-06 AU AU2017206069A patent/AU2017206069A1/en not_active Abandoned
- 2017-01-06 CN CN202211417149.0A patent/CN115814077A/zh active Pending
- 2017-01-06 US US15/400,825 patent/US10287345B2/en active Active
- 2017-01-06 SG SG11201805709RA patent/SG11201805709RA/en unknown
- 2017-01-06 MX MX2018008369A patent/MX2018008369A/es unknown
- 2017-01-06 JP JP2018535391A patent/JP2019504064A/ja active Pending
- 2017-01-06 CN CN201780015496.1A patent/CN109071645A/zh active Pending
- 2017-01-06 EP EP17701024.6A patent/EP3400240A2/en active Pending
-
2018
- 2018-07-05 MX MX2024006564A patent/MX2024006564A/es unknown
- 2018-07-05 MX MX2024006565A patent/MX2024006565A/es unknown
-
2019
- 2019-03-21 US US16/360,142 patent/US10882904B2/en active Active
-
2020
- 2020-10-29 US US17/083,917 patent/US12006359B2/en active Active
-
2022
- 2022-11-21 JP JP2022185469A patent/JP7723649B2/ja active Active
-
2024
- 2024-04-25 US US18/646,693 patent/US20240391989A1/en active Pending
- 2024-06-19 AU AU2024204159A patent/AU2024204159A1/en active Pending
-
2025
- 2025-07-31 JP JP2025128180A patent/JP2025170265A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504064A5 (enExample) | ||
| Zhou et al. | Cytokine signaling in skeletal muscle wasting | |
| JP2018535948A5 (enExample) | ||
| JP2015506944A5 (enExample) | ||
| JP2016536332A5 (enExample) | ||
| CN106068125B (zh) | 治疗脂肪组织积聚的组合物和方法 | |
| JP2013165711A5 (enExample) | ||
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| JP2010520290A5 (enExample) | ||
| US11786585B2 (en) | Anti-IGFBP-3R antibodies and methods of treating an IGFBP-3R expressing cancer | |
| US12338279B2 (en) | Selective and potent inhibitory antibodies of myostatin activation | |
| FI3565592T3 (fi) | Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio | |
| US20130344081A1 (en) | Method of treating amyotrophic lateral sclerosis | |
| JP5068253B2 (ja) | 心臓血管疾患の治療 | |
| CA3028586A1 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| Angelino et al. | Antifibrotic activity of acylated and unacylated ghrelin | |
| US12098129B2 (en) | Pharmaceutical composition for treating fibrosis | |
| WO2018130513A1 (en) | Use of cd47 antibodies | |
| TW201945026A (zh) | 結合erfe之抗體及使用方法 | |
| JP2017501182A5 (enExample) | ||
| CN112236166A (zh) | 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂 | |
| Zhang et al. | Hydroxysafflor yellow A attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting Erk5 signaling | |
| WO2023001305A1 (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| WO2023019232A1 (en) | Anti-il-36r antibodies for the treatment of a fibrotic condition |